Vanda Pharmaceuticals Inc. Operating Income Loss

• Vanda Pharmaceuticals Inc. showed a decrease of -271.8% in Operating Income Loss from 2024 to 2025.
• This data is from Vanda Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Vanda Pharmaceuticals Inc.'s Operating Income Loss has declined by 320.5%.
• Historical annual values: Fiscal year 2025: -$151.17 million | Fiscal year 2024: -$40.66 million | Fiscal year 2023: -$13.95 million | Fiscal year 2022: $6.33 million | Fiscal year 2021: $42.17 million | Fiscal year 2020: $27.24 million | Fiscal year 2019: $22.81 million | Fiscal year 2018: $21.74 million | Fiscal year 2017: -$16.90 million | Fiscal year 2016: -$18.57 million | Fiscal year 2015: -$40.19 million | Fiscal year 2014: $20.06 million | Fiscal year 2013: -$21.20 million | Fiscal year 2012: -$29.18 million | Fiscal year 2011: -$10.71 million | Fiscal year 2010: $8.84 million | Fiscal year 2009: -$35.95 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026